Neurocrine Biosciences (NBIX) investor relations material

Business performance and product portfolio

• Transitioned from a single-product to a multi-product company, now with 20 commercial assets and strong cash flow generation.

• INGREZZA continues double-digit growth nine years post-launch, with 2024 guidance of $2.7–$2.8 billion.

• CRENESSITY and VYKAT XR have established a rare endocrine franchise, with combined quarterly revenues exceeding $250 million and gross margins above 97%.

• Acquisition of Soleno for $2.9 billion adds a second rare endocrine product, immediately accretive and diversifies revenue.

• Non-GAAP net income is around $200 million and growing, supporting reinvestment in R&D at a 30–35% rate.

Product launches and market dynamics

• VYKAT XR, approved for Prader-Willi syndrome, is expected to achieve blockbuster status with peak penetration at the higher end of 30–50%.

• CRENESSITY adoption is steady, with most prescribers starting with one patient and opportunities for deeper penetration as experience grows.

• INGREZZA’s growth is driven by increased diagnosis rates, sales force expansion, and direct-to-consumer advertising.

• Market tailwinds include rising prevalence of target conditions and an expanding prescriber base, especially among advanced practice providers.

• Revenue growth for INGREZZA is expected to be mid-teens in volume, offset by a 4–5% annual price headwind.

Strategic outlook and R&D pipeline

• Pipeline includes 20 clinical programs, with osavampator (MDD, phase III) and dureclidine (schizophrenia, phase III) as headline assets; key data readouts expected in 2027–2028.

• Obesity program (5-HT2A agonist) to deliver patient data in late 2027.

• Muscarinic portfolio aims for differentiation in tolerability and dosing; dureclidine targets schizophrenia and bipolar mania.

• Diversification strategy extends beyond psychiatry to neurology, endocrinology, and immunology.

• Sales force expansion is considered strategically, with current infrastructure deemed sufficient unless new launches require further investment.